1. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009;20(1):81–82.
2. Chowdhury S, Spicer J, Harper P. Hypertension and targeted therapy: part 1. Bevacizumab. Targeted Oncology. 2006;1(2):104–108.
3. Chowdhury S, Spicer J, Harper P. Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF. Targeted Oncology. 2006;1(3):172–178.
4. Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132–143.
5. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009;15(19):5947–5949.
6. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol. 2007;18(6):1117.
7. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol. 1996;27(6):838–844.
8. Wei W, Jin H, Chen ZW, et al. Vascular endothelial growth factor- induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol. 2004;44(5):615–621.
9. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–3476.
10. Dechend R, Luft FC. Angiogenesis factors and preeclampsia. Nature Med. 2008;14(11):1187–1188.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
12. Sunitinib malate (SUTENT ® ) prescribing information. Revised July 2010. 
13. Rini BI, Schiller JH, Fruehauf JP, et al. Association of diastolic blood pressure (dBP) >= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. May 30, 2008 to June 3, 2008. Abstract 3543.
14. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20(2):393–394.
15. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non–small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28(6): 949–954.
16. Friberg G, Kasza K, Vokes EE, et al. Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G). J Clin Oncol. 2005;23(suppl):196s. Abstract 3020.
17. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab. Ann Oncol. 2009;20(2):227–230.
18. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–763.
19. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.
20. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–2524.
21. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3): 205–216.
23. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
24. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–296.
25. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799.
26. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta- analysis. Acta Oncol. 2009;48(1):9–17.
27. Launay-Vacher V, Ayllon J, Janus N, et al. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print November 12, 2009]. Urol Oncol.
28. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604.
29. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27(36):6152–6159.
30. Bamias A, Lainakis G, Manios E, et al. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009;21(3): 347–350.
31. Van Heeckeren WJ, Ortiz J, Cooney MM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007;25(21):2993–2995.
32. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS mes- sage, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3, pt 2):H1054–H1058.
33. van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin micro- vascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21(4):439–446.
34. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmaco- dynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357–371.